Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
about
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging conceptsResponse biomarkers: re-envisioning the approach to tailoring drug therapy for cancerMonitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation studyAre we ready for the 10% solution?Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma PatientsVolume and attenuation computed tomography measurements for interim evaluation of Hodgkin and follicular lymphoma as an additional surrogate parameter for more confident response monitoring: a pilot studyTargeted therapies in renal cell cancer: recent developments in imagingValidation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study.Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.Clinical utility of quantitative imaging.RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.Update on the role of imaging in management of metastatic colorectal cancerTyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.MRI phenotype in renal cancer: is it clinically relevant?Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal CancerThe best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective studyViable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer.Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECISTTumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1.Contrasting effects of sunitinib within in vivo models of metastasis.Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to knowEvaluation of cancer treatment in the abdomen: Trends and advances.Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: the morphologic response criteriaChanges in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular CarcinomaDiffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinomaMetastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumabImaging of renal cell carcinoma: state of the art and recent advances.Imaging assessment of tumor response: past, present and future.Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging.Multiparametric PET/CT in oncology.Metastatic renal cell cancer.
P2860
Q26863654-8BC8DDF0-7C21-4E2D-A68B-577D65B5A1F6Q28074295-7AEB5FDB-D94F-49C6-966D-CA01FE9C23CBQ32176092-B132A8D5-514D-408B-B957-020623928E6AQ33577856-A1D4D0D6-4946-4B7E-B137-24E87AF24D52Q33577894-68E4EAA1-0067-4142-BCF3-BB1D5C9515FBQ33652589-02C11C0D-F47F-4948-973E-096DF1B5EA83Q33745827-BF4E0B6C-A188-43A0-949A-ABBA0D0D69A0Q33770680-3CF50E22-FBF0-40A3-9358-B29251833230Q33869697-1D2C985E-0A6D-4CE3-B767-9BD6E5710A31Q34063323-23F0AA33-AEF7-45EB-9E34-B509118EB7CAQ34088696-C33CB168-7A73-48D7-8801-13DF6483EC57Q34465123-47EE6F2C-379E-47F0-AC09-7424C22B8B66Q34537285-DC84E82E-8D41-4FE5-B686-AB398EEC9C1EQ34656915-F4D172BC-A80F-48B8-B5C0-C95EAD8E078AQ35156636-7F2A103D-FEEB-4430-8A89-5177C6B39140Q35230406-850EADB4-4FBC-430F-BDA2-7A0692E419D5Q35285305-35065542-B61E-4940-95AB-CEF2E0B676BAQ35534962-FE7D6154-C528-44DF-9BD5-25158185DAD7Q35793032-EDB4FE06-05D9-4CAD-AE6D-3E67B158D24EQ35869753-F5C8F588-D38D-4121-B84A-8B51C72699A0Q35918881-1B1B37EB-7CE0-4037-9DE0-789546509831Q35984183-4B4EAAFC-B592-4037-BCED-305C975F8576Q36015295-66C0F037-C7B6-49D3-A288-70D496E324E5Q36084854-EC8C3BFA-3097-4250-B9B9-9E6318C17D79Q36177866-A9363E77-5BD2-4C94-9A93-C359D2AC0DC4Q36394262-C5CA5742-05E2-4175-9938-FA990CF2E919Q36567385-5D7295B5-D03A-4657-BDAC-772BB9209093Q36819466-6C9305C4-53ED-4C89-AA71-BC673F21ADA6Q36832118-2B408A89-23C0-4BA3-BDD7-3C9A3234E90CQ36860539-B0011488-1ABE-46EF-A6EE-40960C641F70Q37185773-59D385E0-B1D9-49AF-A657-38099015FD61Q37236229-AEC605FD-CD7A-4187-9B80-AD59274C2F45Q37245796-519A1C28-7EFB-452E-B484-6F97D273A487Q37559090-CDF35FD0-141A-4C40-9378-72001B9D64F5Q37701127-6257ABD1-B810-4B09-B3E7-3DB2C7E99361Q37819763-14DA53B9-657B-4F58-8279-FF8269CAA570Q37875082-CE05276F-F7E8-4D24-A6E7-301005D51D5CQ37965053-CB778496-AA15-484A-B0FF-D571B598F055Q38047768-F0C79555-1347-486B-BB37-46E9BA2AE4CCQ38141650-18E58BDE-B92F-4101-9E25-DD2B8DB06EDD
P2860
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Assessing tumor response and d ...... ation on contrast-enhanced CT.
@en
Assessing tumor response and d ...... ation on contrast-enhanced CT.
@nl
type
label
Assessing tumor response and d ...... ation on contrast-enhanced CT.
@en
Assessing tumor response and d ...... ation on contrast-enhanced CT.
@nl
prefLabel
Assessing tumor response and d ...... ation on contrast-enhanced CT.
@en
Assessing tumor response and d ...... ation on contrast-enhanced CT.
@nl
P2093
P356
P1476
Assessing tumor response and d ...... ation on contrast-enhanced CT.
@en
P2093
Andrew Dennis Smith
Michael L Lieber
Shetal N Shah
P304
P356
10.2214/AJR.09.2941
P407
P577
2010-01-01T00:00:00Z